SUVN-G3031
- Generic Name
- SUVN-G3031
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H31N3O3
- CAS Number
- 1394808-82-2
- Unique Ingredient Identifier
- 65V47O9NOP
- Background
SUVN-G3031 is under investigation in clinical trial NCT02342041 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 190
- Registration Number
- NCT04072380
- Locations
- 🇺🇸
Santa Monica Clinical Trials, Los Angeles, California, United States
🇺🇸Southern California Institute for Respiratory Diseases, Inc., Los Angeles, California, United States
🇺🇸St. Francis Medical Institute, Clearwater, Florida, United States
A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 24
- Registration Number
- NCT02881294
- Locations
- 🇺🇸
Quintiles, Overland Park, Kansas, United States
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 64
- Registration Number
- NCT02342041
- Locations
- 🇺🇸
Quintiles, Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath